Felicia Hill-Briggs, PhD, states that adherence and quality of life outcomes are equally important as comparative effectiveness research in clinical trials.
In this video, Felicia Hill-Briggs, PhD, discusses how adherence and quality-of-life outcomes are equally important in overall treatment effectiveness data for clinical trials, as it is important to distinguish whether negative treatment effectiveness data are indicative of the performance of the drug itself or poor adherence by the participant. In addition, it’s important to track medication adherence during clinical trials, so that these data can be considered as part of the treatment’s overall effectiveness or ineffectiveness during the review process.
Dr. Hill-Briggs also notes that quality-of-life data are important because it determines whether a patient will continue or maintain a treatment. “Patients have to manage their diseases and medical conditions, particularly diabetes, in the context of living a life and for a lifetime,” says Dr. Hill-Briggs.
Finding the Right Biomarker Is Key to the TIGIT Puzzle, Experts Say
May 12th 2025Data for SKYSCRAPER-01, involving the anti-TIGIT antibody tiragolumab, align with recent bad news for this once-promising therapeutic target. But investigators involved in TIGIT studies say the problem is finding the right biomarker.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
AXS25: Health Policy, Drug Costs, and AI Highlights From the Conference
May 6th 2025Asembia’s AXS25 Summit covered a variety of relevant topics in the pharmaceutical industry, from the effects of the new administration to how artificial intelligence (AI) is reshaping the patience experience.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Addressing KRAS Resistance, RAS(ON) Therapies Find Limelight at AACR
May 5th 2025KRAS-targeted therapies, including daraxonrasib and zoldonrasib, show promise in overcoming resistance in cancer treatment, as highlighted at the 2025 meeting of the American Association for Cancer Research (AACR).
Read More